Abstract
Background Since the outbreak of COVID-19 pandemic, the world began a frantic search for possible prophylactic options. While trials on hydroxychloroquine (HCQ) prophylaxis are ongoing, concrete evidence is lacking. The study aimed to determine the relative efficacy of various doses of oral HCQ in prophylaxis and mitigating the severity of COVID-19 in healthcare workers.
Methods This was a prospective cohort with four arms (high, medium, low dose, and control) of HCQ prophylaxis, used by healthcare workers at a tertiary care center in India. Participants were grouped as per their opting for any one arm on a voluntary basis as per institute policy under the Government guidance. The outcomes studied were COVID-19 positivity by RT-PCR and its severity assessed by WHO COVID-19 severity scale.
Results Total 486 participants were enrolled, of which 29 (6%) opted for low dose, 2 (<1%) medium dose, and none for high dose HCQ while 455 (93.6%) were in the control arm. Of the 164 participants who underwent RT-PCR, 96 (58.2%) tested positive. Out of these 96 positive cases, the majority of them (79 of 96 [82.3%]) were ambulatory and were managed conservatively at home. Only 17.7% (17 of 96) participants, all of them from the control group, required hospitalization with the mild-moderate disease. None of the participants had severe disease, COVID-related complications, ICU stay, or death. The difference in the outcome assessed amongst the various arms was statistically insignificant (p value >0.05).
Conclusion This single-center study demonstrated that HCQ prophylaxis in healthcare workers does not cause a significant reduction in COVID-19 as well as mitigating its severity in those infected. At present, most of the trials have not shown any benefit. The debate continues to rage, should HCQ prophylaxis be given to healthcare workers for chemoprophylaxis?
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2020/06/025593
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was done after institute ethical approval (Institutional Ethics Committee at All India Institute of Medical Sciences, Rishikesh) and as per declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails: m.agarwal95{at}gmail.com, ranka.rajat95{at}gmail.com, ajay.anaes{at}aiimsrishikesh.edu.in, chikaraicon.gaurav{at}gmail.com, suresh.nur{at}aiimsrishikesh.edu.in, ramanuj.samanta{at}gmail.com, rohit.cardio{at}aiimsrishikesh.edu.in, dr.yogeshab{at}gmail.com, sarama.bchem{at}aiimsrishikesh.edu.in, minakshi.dhar{at}rediffmail.com, drprakhar2009{at}gmail.com, arvindgupta.path{at}gmail.com, ubsugandha{at}hotmail.com, manoj.rt{at}aiimsrishikesh.edu.in, ravibina{at}gmail.com,
Data Availability
After obtaining approval from corresponding author, de-identified data can be shared.
